Research progress on therapeutic drugs for rheumatoid arthritis

WANG Jing; ZHAO Qinjie; ZHUO Xiaobin; JIANG Yunyun; YE Guangming

doi:10.3969/j.issn.1006-0111.2019.06.002

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Volume 37 Issue 6

Turn off MathJax

Article Contents

Article Navigation > Journal of Pharmaceutical Practice and Service > 2019 > 37(6): 485-490

WANG Jing, ZHAO Qinjie, ZHUO Xiaobin, JIANG Yunyun, YE Guangming. Research progress on therapeutic drugs for rheumatoid arthritis[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(6): 485-490. doi: 10.3969/j.issn.1006-0111.2019.06.002

Citation:

WANG Jing, ZHAO Qinjie, ZHUO Xiaobin, JIANG Yunyun, YE Guangming. Research progress on therapeutic drugs for rheumatoid arthritis[J]. Journal of Pharmaceutical Practice and Service, 2019, 37(6): 485-490. doi: 10.3969/j.issn.1006-0111.2019.06.002

Research progress on therapeutic drugs for rheumatoid arthritis

doi: 10.3969/j.issn.1006-0111.2019.06.002

1.
Huzhou Clinical College of Auhui medical University/No. 98 Hospital of PLA, Huzhou 230032, China
2.
School of Pharmacy, Naval Medical University, Shanghai 200433, China
3.
No. 101 Hospital of PLA, Wuxi 214044, China

Received Date: 2019-06-03
Rev Recd Date: 2019-10-09

Abstract

Rheumatoid arthritis (RA) is a common autoimmune disease characterized by joint damage and synovial inflammation.Two major classes of RA drugs,including small molecule synthetic RA drugs and macromolecular biological RA drugs (TNF inhibitors、B cell inhibitors、T cell inhibitors、IL inhibitors、target RANKL biologics、target GM-CSF biologics) were reviewed in this paper,focusing on the therapeutic mechanisms of these two classes of drugs.In addition the latest therapeutic target for rheumatoid arthritis was also summarized,which provided a potential new direction for the treatment of patients with rheumatoid arthritis.
- rheumatoid arthritis,
- therapeutic drugs,
- biopharmaceutics

References

[1]	CROSS M,SMITH E,HOY D,et al.The global burden of rheumatoid arthritis:estimates from the global burden of disease 2010 study[J].Ann Rheum Dis,2014,73(7):1316-1322.
[2]	SCHELLEKENS G A,DE JONG B A,VAN DEN HOOGEN F H,et al.Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies[J].J Clin Invest,1998,101(1):273-281.
[3]	SMOLEN J S,ALETAHA D,MCINNES I B.Rheumatoid arthritis[J].Lancet,2016,388(10055):2023-2038.
[4]	VISSER K,VAN DER HEIJDE D.Optimal dosage and route of administration of methotrexate in rheumatoid arthritis:a systematic review of the literature[J].Ann Rheum Dis,2009,68(7):1094-1099.
[5]	BROWN P M,PRATT A G,ISAACS J D.Mechanism of action of methotrexate in rheumatoid arthritis,and the search for biomarkers[J].Nat Rev Rheumatol,2016,12(12):731-742.
[6]	HERRMANN M L,SCHLEYERBACH R,KIRSCHBAUM B J.Leflunomide:an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases[J].Immunopharmacology,2000,47(2-3):273-289.
[7]	STRAND V,COHEN S,SCHIFF M,et al.Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate.leflunomide rheumatoid arthritis investigators group[J].Arch Intern Med,1999,159(21):2542-2550.
[8]	LINARES V,ALONSO V,DOMINGO J L.Oxidative stress as a mechanism underlying sulfasalazine-induced toxicity[J].Expert Opin Drug Saf,2011,10(2):253-263.
[9]	PLOSKER G L,CROOM K F.Sulfasalazine:a review of its use in the management of rheumatoid arthritis[J].Drugs,2005,65(13):1825-1849.
[10]	LEE C K,LEE E Y,CHUNG S M,et al.Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB,osteoprotegerin,and receptor activator of nuclear factor kappaB ligand[J].Arthritis Rheum,2004,50(12):3831-3843.
[11]	SAMES E,PATERSON H,LI C.Hydroxychloroquine-induced agranulocytosis in a patient with long-term rheumatoid arthritis[J].Eur J Rheumatol,2016,3(2):91-92.
[12]	KATZ S J,RUSSELL A S.Re-evaluation of antimalarials in treating rheumatic diseases:re-appreciation and insights into new mechanisms of action[J].Curr Opin Rheumatol,2011,23(3):278-281.
[13]	KIM J W,KIM YY,LEE H,et al.Risk of retinal toxicity in longterm users of hydroxychloroquine[J].J Rheumatol,2017,44(11):1674-1679.
[14]	YAMAOKA K,KUBO S,SONOMOTO K,et al.JAK inhibitor:tofacitinib,a new disease modifying anti-rheumatic drug[J].Inflamm Regen,2011,31(4):349-353.
[15]	SEMERANO L,DECKER P,CLAVEL G,et al.Developments with investigational Janus kinase inhibitors for rheumatoid arthritis[J].Expert Opin Investig Drugs,2016,25(12):1355-1359.
[16]	AND M F,MAINI R N.Anti-tnf alpha therapy of rheumatoid arthritis:what have we learned[J].Ann Rev Immunol,2001,19(1):163-196.
[17]	GAO G H,LI J,XIE H W,et al.Therapeutic effect of infliximab on moderate and severe active rheumatoid arthritis[J].J South Med Univ,2010,30(4):724-726.
[18]	BRAUN J,KAY J.The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis[J].Expert Opin Drug Saf,2017,16(3):289-302.
[19]	WEINBLATT M E,KEYSTONE E C,FURST D E,et al.Adalimumab,a fully human anti-tumor necrosis factor alpha monoclonal antibody,for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate:the ARMADA trial[J].Arthritis Rheum,2003,48(1):35-45.
[20]	WEINBLATT M E,KEYSTONE E C,FURST D E,et al.Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis:ARMADA 4 year extended study[J].Ann Rheum Dis,2006,65(6):753-759.
[21]	JAMAL S,PATRA K,KEYSTONE E C.Adalimumab response in patients with early versus established rheumatoid arthritis:DE019 randomized controlled trial subanalysis[J].Clin Rheumatol,2009,28(4):413-419.
[22]	SCHIFF M H,BURMESTER G R,KENT J D,et al.Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis[J].Ann Rheum Dis,2006,65(7):889-894.
[23]	YATES M,HAMILTON L E,ELENDER F,et al.Is etanercept 25 mg once weekly as effective as 50 mg at maintaining response in patients with ankylosing spondylitis? A randomized control trial[J].J Rheumatol,2015,42(7):1177-1185.
[24]	ARENDS S,BROUWER E,EFDE M,et al.Long-term drug survival and clinical effectiveness of etanercept treatment in patients with ankylosing spondylitis in daily clinical practice[J].Clin Exp Rheumatol,2017,35(1):61-68.
[25]	KAY J,FLEISCHMANN R,KEYSTONE E,et al.Golimumab 3-year safety update:an analysis of pooled data from the long-term extensions of randomised,double-blind,placebo-controlled trials conducted in patients with rheumatoid arthritis,psoriatic arthritis or ankylosing spondylitis[J].Ann Rheum Dis,2015,74(3):538-546.
[26]	NESBITT A,FOSSATI G,BERGIN M,et al.Mechanism of action of certolizumab pegol(CDP870):in vitro comparison with other anti-tumor necrosis factor alpha agents[J].Inflamm Bowel Dis,2007,13(11):1323-1332.
[27]	MÉLET J,MULLEMAN D,GOUPILLE P,et al.Rituximab-induced T cell depletion in patients with rheumatoid arthritis:association with clinical response[J].Arthritis Rheum,2013,65(11):2783-2790.
[28]	张凤,张玲玲,魏伟.B细胞活化因子及其受体介导的信号通路参与类风湿关节炎病理机制研究进展[J].中国免疫学杂志,2016,32(2):258-261.
[29]	JIN X Z,DING C H.Belimumab-an anti-BLyS human monoclonal antibody for rheumatoid arthritis[J].Expert Opin Biol Ther,2013,13(2):315-322.
[30]	CHEN L P,FLIES D B.Molecular mechanisms of T cell co-stimulation and co-inhibition[J].Nat Rev Immunol,2013,13(4):227-242.
[31]	RAIMONDO M G,BIGGIOGGERO M,CROTTI C,et al.Profile of sarilumab and its potential in the treatment of rheumatoid arthritis[J].Drug Des Dev Ther,2017,Volume 11:1593-1603.
[32]	余琛琳,宗英,张晓芳,等.IL-1抑制剂研发策略及临床应用进展[J].中国新药杂志,2014,23(10):1121-1126.
[33]	CHIU Y G,RITCHLIN C T.Denosumab:targeting the RANKL pathway to treat rheumatoid arthritis[J].Expert Opin Biol Ther,2017,17(1):119-128.
[34]	YUE J,GRIFFITH J F,XIAO F,et al.Repair of bone erosion in rheumatoid arthritis by denosumab:A high-resolution peripheral quantitative computed tomography study[J].Arthritis Care Res (Hoboken),2017,69(8):1156-1163.
[35]	BURMESTER G R,MCINNES I B,KREMER J,et al.Arandomised phase IIb study of mavrilimumab,a novel GM-CSF receptor alpha monoclonal antibody,in the treatment of rheumatoid arthritis[J].Ann Rheum Dis,2017,76(6):1020-1030.
[36]	ELSHABRAWY H A,ESSANI A E,SZEKANECZ Z,et al.TLRs,future potential therapeutic targets for RA[J].Autoimmun Rev,2017,16(2):103-113.
[37]	FECHTNER S,FOX D A,AHMED S.Transforming growth factor β activated kinase 1:a potential therapeutic target for rheumatic diseases[J].Rheumatology (Oxford),2017,56(7):1060-1068.
[38]	CHEUNG TT,MCINNES I B.Future therapeutic targets in rheumatoid arthritis?[J].Semin Immunopathol,2017,39(4):487-500.
[39]	BENHAM H,NEL H J,LAW S C,et al.Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype-positive rheumatoid arthritis patients[J].Sci Transl Med,2015,7(290):290ra87.
[40]	WHANG J A,CHANG B Y.Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis[J].Drug Discov Today,2014,19(8):1200-1204.

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views(6999) PDF downloads(1216) Cited by()

Proportional views

Research progress on therapeutic drugs for rheumatoid arthritis

1. Huzhou Clinical College of Auhui medical University/No. 98 Hospital of PLA, Huzhou 230032, China

2. School of Pharmacy, Naval Medical University, Shanghai 200433, China

3. No. 101 Hospital of PLA, Wuxi 214044, China

Received Date: 2019-06-03

Rev Recd Date: 2019-10-09

Key words:

Abstract: Rheumatoid arthritis (RA) is a common autoimmune disease characterized by joint damage and synovial inflammation.Two major classes of RA drugs,including small molecule synthetic RA drugs and macromolecular biological RA drugs (TNF inhibitors、B cell inhibitors、T cell inhibitors、IL inhibitors、target RANKL biologics、target GM-CSF biologics) were reviewed in this paper,focusing on the therapeutic mechanisms of these two classes of drugs.In addition the latest therapeutic target for rheumatoid arthritis was also summarized,which provided a potential new direction for the treatment of patients with rheumatoid arthritis.

HTML

Reference (40)

[1]	CROSS M,SMITH E,HOY D,et al.The global burden of rheumatoid arthritis:estimates from the global burden of disease 2010 study[J].Ann Rheum Dis,2014,73(7):1316-1322.
[2]	SCHELLEKENS G A,DE JONG B A,VAN DEN HOOGEN F H,et al.Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies[J].J Clin Invest,1998,101(1):273-281.
[3]	SMOLEN J S,ALETAHA D,MCINNES I B.Rheumatoid arthritis[J].Lancet,2016,388(10055):2023-2038.
[4]	VISSER K,VAN DER HEIJDE D.Optimal dosage and route of administration of methotrexate in rheumatoid arthritis:a systematic review of the literature[J].Ann Rheum Dis,2009,68(7):1094-1099.
[5]	BROWN P M,PRATT A G,ISAACS J D.Mechanism of action of methotrexate in rheumatoid arthritis,and the search for biomarkers[J].Nat Rev Rheumatol,2016,12(12):731-742.
[6]	HERRMANN M L,SCHLEYERBACH R,KIRSCHBAUM B J.Leflunomide:an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases[J].Immunopharmacology,2000,47(2-3):273-289.
[7]	STRAND V,COHEN S,SCHIFF M,et al.Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate.leflunomide rheumatoid arthritis investigators group[J].Arch Intern Med,1999,159(21):2542-2550.
[8]	LINARES V,ALONSO V,DOMINGO J L.Oxidative stress as a mechanism underlying sulfasalazine-induced toxicity[J].Expert Opin Drug Saf,2011,10(2):253-263.
[9]	PLOSKER G L,CROOM K F.Sulfasalazine:a review of its use in the management of rheumatoid arthritis[J].Drugs,2005,65(13):1825-1849.
[10]	LEE C K,LEE E Y,CHUNG S M,et al.Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB,osteoprotegerin,and receptor activator of nuclear factor kappaB ligand[J].Arthritis Rheum,2004,50(12):3831-3843.
[11]	SAMES E,PATERSON H,LI C.Hydroxychloroquine-induced agranulocytosis in a patient with long-term rheumatoid arthritis[J].Eur J Rheumatol,2016,3(2):91-92.
[12]	KATZ S J,RUSSELL A S.Re-evaluation of antimalarials in treating rheumatic diseases:re-appreciation and insights into new mechanisms of action[J].Curr Opin Rheumatol,2011,23(3):278-281.
[13]	KIM J W,KIM YY,LEE H,et al.Risk of retinal toxicity in longterm users of hydroxychloroquine[J].J Rheumatol,2017,44(11):1674-1679.
[14]	YAMAOKA K,KUBO S,SONOMOTO K,et al.JAK inhibitor:tofacitinib,a new disease modifying anti-rheumatic drug[J].Inflamm Regen,2011,31(4):349-353.
[15]	SEMERANO L,DECKER P,CLAVEL G,et al.Developments with investigational Janus kinase inhibitors for rheumatoid arthritis[J].Expert Opin Investig Drugs,2016,25(12):1355-1359.
[16]	AND M F,MAINI R N.Anti-tnf alpha therapy of rheumatoid arthritis:what have we learned[J].Ann Rev Immunol,2001,19(1):163-196.
[17]	GAO G H,LI J,XIE H W,et al.Therapeutic effect of infliximab on moderate and severe active rheumatoid arthritis[J].J South Med Univ,2010,30(4):724-726.
[18]	BRAUN J,KAY J.The safety of emerging biosimilar drugs for the treatment of rheumatoid arthritis[J].Expert Opin Drug Saf,2017,16(3):289-302.
[19]	WEINBLATT M E,KEYSTONE E C,FURST D E,et al.Adalimumab,a fully human anti-tumor necrosis factor alpha monoclonal antibody,for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate:the ARMADA trial[J].Arthritis Rheum,2003,48(1):35-45.
[20]	WEINBLATT M E,KEYSTONE E C,FURST D E,et al.Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis:ARMADA 4 year extended study[J].Ann Rheum Dis,2006,65(6):753-759.
[21]	JAMAL S,PATRA K,KEYSTONE E C.Adalimumab response in patients with early versus established rheumatoid arthritis:DE019 randomized controlled trial subanalysis[J].Clin Rheumatol,2009,28(4):413-419.
[22]	SCHIFF M H,BURMESTER G R,KENT J D,et al.Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis[J].Ann Rheum Dis,2006,65(7):889-894.
[23]	YATES M,HAMILTON L E,ELENDER F,et al.Is etanercept 25 mg once weekly as effective as 50 mg at maintaining response in patients with ankylosing spondylitis? A randomized control trial[J].J Rheumatol,2015,42(7):1177-1185.
[24]	ARENDS S,BROUWER E,EFDE M,et al.Long-term drug survival and clinical effectiveness of etanercept treatment in patients with ankylosing spondylitis in daily clinical practice[J].Clin Exp Rheumatol,2017,35(1):61-68.
[25]	KAY J,FLEISCHMANN R,KEYSTONE E,et al.Golimumab 3-year safety update:an analysis of pooled data from the long-term extensions of randomised,double-blind,placebo-controlled trials conducted in patients with rheumatoid arthritis,psoriatic arthritis or ankylosing spondylitis[J].Ann Rheum Dis,2015,74(3):538-546.
[26]	NESBITT A,FOSSATI G,BERGIN M,et al.Mechanism of action of certolizumab pegol(CDP870):in vitro comparison with other anti-tumor necrosis factor alpha agents[J].Inflamm Bowel Dis,2007,13(11):1323-1332.
[27]	MÉLET J,MULLEMAN D,GOUPILLE P,et al.Rituximab-induced T cell depletion in patients with rheumatoid arthritis:association with clinical response[J].Arthritis Rheum,2013,65(11):2783-2790.
[28]	张凤,张玲玲,魏伟.B细胞活化因子及其受体介导的信号通路参与类风湿关节炎病理机制研究进展[J].中国免疫学杂志,2016,32(2):258-261.
[29]	JIN X Z,DING C H.Belimumab-an anti-BLyS human monoclonal antibody for rheumatoid arthritis[J].Expert Opin Biol Ther,2013,13(2):315-322.
[30]	CHEN L P,FLIES D B.Molecular mechanisms of T cell co-stimulation and co-inhibition[J].Nat Rev Immunol,2013,13(4):227-242.
[31]	RAIMONDO M G,BIGGIOGGERO M,CROTTI C,et al.Profile of sarilumab and its potential in the treatment of rheumatoid arthritis[J].Drug Des Dev Ther,2017,Volume 11:1593-1603.
[32]	余琛琳,宗英,张晓芳,等.IL-1抑制剂研发策略及临床应用进展[J].中国新药杂志,2014,23(10):1121-1126.
[33]	CHIU Y G,RITCHLIN C T.Denosumab:targeting the RANKL pathway to treat rheumatoid arthritis[J].Expert Opin Biol Ther,2017,17(1):119-128.
[34]	YUE J,GRIFFITH J F,XIAO F,et al.Repair of bone erosion in rheumatoid arthritis by denosumab:A high-resolution peripheral quantitative computed tomography study[J].Arthritis Care Res (Hoboken),2017,69(8):1156-1163.
[35]	BURMESTER G R,MCINNES I B,KREMER J,et al.Arandomised phase IIb study of mavrilimumab,a novel GM-CSF receptor alpha monoclonal antibody,in the treatment of rheumatoid arthritis[J].Ann Rheum Dis,2017,76(6):1020-1030.
[36]	ELSHABRAWY H A,ESSANI A E,SZEKANECZ Z,et al.TLRs,future potential therapeutic targets for RA[J].Autoimmun Rev,2017,16(2):103-113.
[37]	FECHTNER S,FOX D A,AHMED S.Transforming growth factor β activated kinase 1:a potential therapeutic target for rheumatic diseases[J].Rheumatology (Oxford),2017,56(7):1060-1068.
[38]	CHEUNG TT,MCINNES I B.Future therapeutic targets in rheumatoid arthritis?[J].Semin Immunopathol,2017,39(4):487-500.
[39]	BENHAM H,NEL H J,LAW S C,et al.Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype-positive rheumatoid arthritis patients[J].Sci Transl Med,2015,7(290):290ra87.
[40]	WHANG J A,CHANG B Y.Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis[J].Drug Discov Today,2014,19(8):1200-1204.

Message Board

Research progress on therapeutic drugs for rheumatoid arthritis

doi: 10.3969/j.issn.1006-0111.2019.06.002

Abstract

References

Proportional views

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Related

Proportional views